18F-deoxyglucose and the assessment of myocardial viability

Seminars in Nuclear Medicine

Volumn 32, Issue 1, 2002, Pages 60-69

  Schelbert, Heinrich R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FATTY ACID; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUCOSE DERIVATIVE; INSULIN; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; GLUCOSE METABOLISM; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE PERFUSION; HEART MUSCLE REVASCULARIZATION; HUMAN; OXIDATION; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING ORGAN SYSTEMS; BLOOD FLOW; COMPUTER ASSISTED EMISSION TOMOGRAPHY; GLUCOSE BLOOD LEVEL; HEART; HEART MUSCLE; METABOLISM; METHODOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW; SCINTISCANNING;

ANIMALS; BLOOD GLUCOSE; CORONARY DISEASE; FLUORODEOXYGLUCOSE F18; HEART; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIUM; RADIOPHARMACEUTICALS; REGIONAL BLOOD FLOW; TISSUE SURVIVAL; TOMOGRAPHY, EMISSION-COMPUTED; VENTRICULAR FUNCTION, LEFT;

EID: 0036007344     PISSN: 00012998     EISSN: None     Source Type: Journal    
DOI: 10.1053/snuc.2002.29274     Document Type: Article

References (77)

1. Investigation of [18F] 2-fluoro-2-deoxyglucose for the measure of myocardial glucose metabolism
2. Application of annihilation coincidence detection to transaxial reconstruction tomography
3. Transaxial tomographic imaging of canine myocardium with 11C-palmitic acid
4. Positron tomography with deoxyglucose for estimating local myocardial glucose metabolism
5. Myocardial glucose uptake measured with fluorodeoxyglucose: A proposed method to account for variable lumped constants
6. 18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake
7. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and Fluorine-18 deoxyglucose
8. Factors affecting myocardial 2-[F-18]fluoro-2-deoxy-D-glucose uptake in positron emission tomography studies of normal humans
9. The metabolism of the heart
10. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data
11. Parametric images of myocardial metabolic rate of glucose generated from dynamic cardiac PET and 2-[18F]fluoro-2-deoxy-d-glucose studies
12. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo
13. The glucose fatty acid cycle: Its role in insulin sensitivity and the metabolic disturbances in diabetes mellitus
14. Nonuniformity in myocardial accumulation of fluorine-18-fluorodeoxyglucose in normal fasted humans
15. Myocardial ischemia - Metabolic pathways and implications of increased glycolysis
16. C-11 labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. II. Kinetics of C- 11 palmitic acid in acutely ischemic myocardium
17. C-11 palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron computed tomography. IV. In vivo demonstration of impaired fatty acid oxidation in acute myocardial ischemia
18. Quantitative assessment of prolonged metabolic abnormalities in reperfused canine myocardium
19. 18Fluoro-2-deoxyglucose and positron emission computed tomography
20. Regional myocardial metabolism in patients with acute myocardial infarction assessed by positron emission tomography
21. Regional blood flow, oxidative metabolism, and glucose utilization in patients with recent myocardial infarction
22. Sustained nonoxidative glucose utilization and depletion of glycogen in reperfused canine myocardium
23. Identification and differentiation of resting myocardial ischemia and infarction in man with positron computed tomography 18F-labeled fluorodeoxyglucose and N-13 ammonia
24. A perspective on the three large multicenter randomized clinical trials of coronary bypass surgery for chronic stable angina
25. The stunned myocardium: Prolonged, postischemic ventricular dysfunction
26. Glucose for the heart
27. Ultrastructural correlates of left ventricular contraction abnormalities in patients with chronic ischemic heart disease: Determinations of reversible segmental asynergy post-revascularization surgery
28. Structural aspects of the chronic hibernating myocardium in man
29. Molecular changes of titin in left ventricular dysfunction as a result of chronic hibernation
30. Expression of myocardial glucose transporter (GLUT) mRNAs in patients with advanced coronary artery disease (CAD)
31. Dedifferentiated cardiomyocytes from chronic hibernating myocardium are ischemia-tolerant
32. Glucose metabolism in the ischemic heart
33. Hibernating myocardium: An incomplete adaptation to ischemia
34. A self-perpetuating vicious cycle of tissue damage in human hibernating myocardium
35. Reversibility of cardiac wall motion abnormalities predicted by positron tomography
36. Improvement of severely reduced left ventricular function after surgical revascularization in patients with preoperative myocardial infarction
37. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease
38. SPECT thallium-201 tomography and positron tomography using N-13 ammonia and F-18 fluorodeoxyglucose in coronary heart disease
39. Prediction of reversible ischemia after coronary artery bypass grafting by positron emission tomography
40. Prediction by postexercise fluoro-18 deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization
41. Metabolic responses of hibernating and infarcted myocardium to revascularization: A follow-up study of regional perfusion, function, and metabolism
42. Functional status and quality of life in patients with heart failure undergoing coronary bypass surery after assessment of myocardial viability
43. F18-fluorodeoxyglucose single-photon emission computed tomography predicts functional outcome of dyssynergic myocardium after surgical revascularization
44. Comparison of fluorine-18-FDG with rest-redistribution thallium-201 SPECT to delineate viable myocardium and predict functional recovery after revascularization
45. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by fluorine-18 fluorodeoxyglucose single-photon emission computed tomography
46. Quantitative analysis of FDG and T1-201 SPECT for the prediction of functional outcome after revascularization
47. Early assessment of regional myocardial blood flow and metabolism in thrombolysis in myocardial infarction flow grade 3 reperfused myocardial infarction using carbon-11-acetate
48. Importance of flow/metabolism studies in predicting late recovery of function following reperfusion in patients with acute myocardial infarction
49. Results of coronary artery surgery in patients with poor left ventricular function (CASS)
50. A randomized trial of coronary artery bypass surgery. Survival of patients with low ejection fraction
51. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography
52. Quantitative relation of myocardial infarct size and myocardial viability by positron emission tomography to left ventricular ejection fraction and 3-year mortality with and without revascularization
53. Prognostic value of an increase in fluorine-18 deoxyglucose uptake in patients with myocardial infarction: Comparison with stress thallium imaging
54. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction
55. Long-term survival of patients with coronary artery disease and left ventricular dysfunction: Implications for the role of myocardial viability assessment in management decisions
56. Prognosis of patients with left ventricular dysfunction, with and without viable myocardium infarction
57. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease
58. Delay in revascularization is associated with increased mortality rate in patients with severe left ventricular dysfunction and viable myocardium on fluorine 18-fluorodeoxyglucose positron emission tomography imagine
59. Coronary artery bypass surgery as treatment for ischemic heart failure: The predictive value of viability assessment with quantitative positron emission tomography for symptomatic and functional outcome
60. Utility of positron emission tomography in predicting cardiac events and survival in patients with coronary artery disease and severe left ventricular dysfunction
61. Assessment of CABG-related risk in patients with CAD and LVD. Contribution of PET with [18F]FDG to the assessment of myocardial viability
62. Coronary revascularization in the treatment of moderate and severe postischemic left ventricular dysfunction
63. PET scan predicts recovery of left ventricular function after coronary artery bypass operation
64. Blood flow-metabolism imaging with positron emission tomography in patients with diabetes mellitus for the assessment of reversible left ventricular contractile dysfunction
65. Coronary surgery can be an alternative to heart transplantation in selected patients with end-stage ischemic heart disease
66. Noninvasive assessment of myocardial viability by positron emission tomography with 11C acetate in patients with old myocardial infarction. Usefulness of low-dose dobutamine infusion
67. 11C-acetate and positron emission tomography
68. Usefulness of positron emission tomography in defining myocardial viability in patients referred for cardiac transplantation
69. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty
70. Time course of functional recovery after coronary artery bypass graft surgery in patients with chronic left ventricular ischemic dysfunction
71. Quantitative relation between myocardial viability and improvement in heart failure symptoms after revascularization in patients with ischemic cardiomyopathy
72. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: Comparison of pooled data
73. Myocardial viability assessment in ischemic cardiomyopathy: Benefits of coronary revascularization
74. Prevalence of myocardial viability as detected by positron emission tomography in patients with ischemic cardiomyopathy
75. Fatty acid uptake is preserved in chronically dysfunctional but viable myocardium
76. Comparison of myocardial uptake of copper pyruvaldehyde thiosemicarbazone with N-13 ammonis in humans by PET
77. Role of positron emission tomographic assessment of myocardial viability in the management of patients who are referred for cardiac transplantation